Board of Directors
Stéphane Verdood – Non-executive Director; Chairman of the Board
Stéphane Verdood is a non-executive director and chairperson of the board of Apitope, having joined in 2008. He was appointed upon proposal of Vesalius Biocapital. Mr. Verdood has 25 years of experience as a business consultant in the healthcare, pharmaceutical and biotechnology industries. Mr Verdood worked for more than 15 years at Arthur Andersen in the areas of business consulting and the pharmaceutical industry. Mr Verdood merged and reorganised hospitals in Europe and re-engineered European pharmaceutical companies in the areas of research and development, distribution and sales. Mr Verdood founded Andersen Business Consulting in Belgium in 1995, and co-founded Value for Growth in 2001 as venture coach of mainly young biotechnology companies. He assisted more than 10 start-up companies in raising funds. Mr Verdood holds a M.Sc. in commercial engineering as well as an MBA from the University of Leuven.
Keith F. Martin, PhD, MIoD, MRPharmS – Non-executive Director
Keith Martin is chief executive officer of Apitope. Dr Martin has enjoyed a career of more than 30 years in both large pharmaceutical companies and early stage biopharmaceutical companies. Dr Martin has held senior positions in research and development and corporate and business development as well as both executive and non-executive board positions with management and leadership roles in the UK, Belgium, the US and Spain. In addition, Dr Martin has developed products from bench to market and realised value through significant licensing deals as well being experienced in grants and venture investment. Dr Martin has been CEO of Apitope since April 2006.
Prior to that role, as BTG’s Global Director of Life Sciences, he was responsible for an extensive portfolio of product candidates and licensee marketed products. As Deputy Head of Biology at BASF Pharma, he developed six CNS compounds from the bench through to Phase I and was a key member of the team that developed two products to full market approval in the US and the UK.
Dr Martin began his research career as a PhD student at the University of Bath. He then held a Wellcome Trust Fellowship in Mental Health at Nottingham University Medical School in addition to a NATO Exchange Fellowship to Princeton University Psychology Department and has an extensive list of publications and patents.
Katleen Vandersmissen, PhD - Non-executive Director
Kathleen Vandersmissen is Head of Health & Care at LRM, an investment company which develops and fosters economic growth in Limburg (Belgium). She is a board member of several portfolio companies such as EpiGaN and Bedal. Before LRM, she worked as a consultant for McKinsey & Co. and held positions at Umicore in R&D and Investor Relations.
She graduated summa cum laude from the University of Leuven in Chemistry and obtained a PhD in science from the same university. Later she obtained a MBA in Corporate Finance from the University of Leuven and a post graduate in Corporate Law from HUB-EHSAL.
Brenig Preest BSc, FCA, DipFS – Non-executive Director
Brenig Preest is a non-executive director of Apitope, appointed upon proposal of WSLF. Mr Preest is a founder and Investment Director of Arthurian Life Sciences Ltd, which manages WLSF and which was acquired by Arix Bioscience PLC in 2016. Mr Preest has over 23 years in the life science and finance sector, the majority of which has been in venture capital. He has led over 50 venture and growth capital investments and over the last 17 years has been a Board member of a number of public and private high growth companies. He has led the majority of investments from the WLSF. Mr Preest began his career at GE Healthcare, then PwC and Ernst and Young as a corporate financier. Mr Preest studied pharmacology at Cardiff University and Financial Strategy at Oxford Said, where he achieved a distinction. He is also a chartered accountant.
William Jenkins, M.D. - Non-executive Independent Director
Dr Jenkins has a wealth of pharmaceutical industry experience following a 30 year career in clinical medicine and research. He held senior posts at Glaxo as Head of Worldwide Clinical Research and at Ciba-Geigy and then Novartis as Global Head of Medicine, Clinical Development & Regulatory Affairs. During that time he was responsible for the development of drugs such as Zofran, Imigran, Serevent, Diovan & Gleevec. Since 1999, Dr Jenkins has been a consultant to the pharmaceutical industry and a member of several boards including Ablynx, BTG, Tanox, Monogram Biosciences, Eurand, Evotec, Acambis and Consort Medical, as well as a chairman or member of several scientific advisory boards.